Testing a new cell therapy for hard-to-treat blood cancers

Plain-English translation of NCT07093411 on ClinicalTrials.gov ↗ · Source last updated August 2025 · Translation generated June 2026 · How we translate trials

Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.

What is this trial?

This early-phase trial is testing whether LUCAR-E9D and LUCAR-E9K—specially engineered cell therapies designed to target cancer cells—can be safe and effective for people with B-cell non-Hodgkin lymphoma that has returned or stopped responding to standard treatments. The treatment involves a single infusion of these cells after you receive chemotherapy to prepare your body. Researchers want to understand how well this medication works and what side effects it may cause.

Many patients with B-cell non-Hodgkin lymphoma don't respond well to standard chemotherapy or their cancer comes back. This trial exists to explore whether a new type of cell therapy—one that targets two key markers on cancer cells—could offer hope to patients who have limited options.

Do you qualify?

You likely qualify if…

you are at least 18 years old and no older than 75
you have been diagnosed with B-cell non-Hodgkin lymphoma that expresses CD19 or CD20
your cancer has either not responded to initial treatment or has returned within 12 months of your last chemotherapy
you have at least one tumor that can be measured on imaging
you are in overall good health (ECOG performance status of 0 or 1, meaning you can care for yourself and are active most of the day)
you have a life expectancy of at least 3 months

You likely don't qualify if…

you have an active cancer other than B-cell non-Hodgkin lymphoma
you have active graft-versus-host disease (a complication from a prior bone marrow transplant) or are taking medications to suppress your immune system for this condition
you have active cancer involvement in your brain or spinal cord
you have a bleeding disorder or are currently experiencing significant bleeding
you are currently taking long-term steroid or immunosuppressant medications for chronic conditions
you have active, severe infections or unstable autoimmune diseases

What participation looks like

You will first go through screening to confirm you qualify. Then you'll receive lymphodepleting chemotherapy (chemotherapy designed to prepare your body for the cell therapy). After that, you'll receive a single infusion of the medication. The trial includes several follow-up visits and tests to monitor how you respond and watch for any side effects. The entire study involves screening, pre-treatment, treatment, and follow-up phases, with a target of about 48 patients enrolled.

AI-generated summary from trial data · Jun 6, 2026 · Not medical advice

Trial locations(3 sites)

China

The First Affiliated Hospital of USTC (Anhui Provincial Hospital), Hefei

The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an

Affiliated Hospital of Xuzhou Medical University, Xuzhou